Drugs moving into the clinic: 12
The twelfth in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
Sponsor | Name | Indication | Mechanism |
---|---|---|---|
Exelixis | XL999 | Oncology - non-small cell lung cancer | Inhibits receptor tyrosine kinases (RTKs): FGFR, VEGFR and PDGFR. Plus inhibits FLT3 - acts against tumour vasculature and proliferation. N.B. reinitiation following Phase II adverse cardiovascular events led to FDA trial design review |
Exelixis | XL765 | Oncology - undisclosed but preclinical studies in breast, lung, ovarian, and prostate cancers, and gliomas | Phospho- inositide-3 kinase (PI3K) inhibitor. Also inhibits mammalian target of rapamycin (mTOR) |
SuperGen | MP470 | Oncology - advanced stage solid tumours | Multi-targeted tyrosine kinase inhibitor: MET, RET and the mutant forms of KIT, PDGFR and FLT3 as well as suppresses the Rad51 protein |
RegenerX | T-beta-4 | Wound healing - Cardio-vascular (post heart attack). N.B. also in PII for chronic dermal and ophthalmic wound healing. | 43 amino-acid peptide synthetic analog of T-beta-4 - the major actin-regulating molecule in most mammalian cells and plays an important role in the regeneration, remodeling, and healing of injured or damaged tissues. N.B. IND application submission |
Pharmexa- Epimmune & Bavarian Nordic | Combined EP1233 & MVA-BN32 Polytope | Anti-infectives and Vaccines - HIV/AIDS | Epitope-based DNA vaccine against HIV which activates both helper cells (HTL) and killer cells (CTL). Combined with an jointly owned epitope-matched MVA (Modified Vaccinia Ankara) viral vector vaccine. |
Enzon Pharma- ceuticals | PEG-SN38 | Oncology - solid tumors or lymphoma | Topo- isomerase I inhibitor to relieve strain in DNA by enabling reversible single strand breaks. Pegylated form of SN38 - the active metabolite of Pfizer's Camptosar (irinotecan). N.B. IND accepted |
Targeted Genetics & University College London's Institute of Ophthalmology, Moorfields Eye Hospital | RPE65 | Blindness (childhood) | Adeno-associated virus (AAV) vector to deliver a normal copy of the RPE65 gene to treat gene defect that prevents normal function of the retina |